BR112023018607A2 - Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior - Google Patents
Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maiorInfo
- Publication number
- BR112023018607A2 BR112023018607A2 BR112023018607A BR112023018607A BR112023018607A2 BR 112023018607 A2 BR112023018607 A2 BR 112023018607A2 BR 112023018607 A BR112023018607 A BR 112023018607A BR 112023018607 A BR112023018607 A BR 112023018607A BR 112023018607 A2 BR112023018607 A2 BR 112023018607A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- depressive disorder
- major depressive
- disubstituted
- steroid
- Prior art date
Links
- 208000024714 major depressive disease Diseases 0.000 title abstract 4
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- VVUQRXPUVKXAIO-XFUVECHXSA-N 19-nor-5-androstenediol Chemical compound C1[C@@H](O)CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 VVUQRXPUVKXAIO-XFUVECHXSA-N 0.000 title 1
- 238000011269 treatment regimen Methods 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000011221 initial treatment Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior. a presente revelação está relacionado aos métodos de tratamento de transtorno depressivo maior (mdd) em um indivíduo necessitado por (i) realização de um esquema de tratamento inicial no indivíduo que compreende a administração de uma quantidade terapeuticamente eficaz de composto (1), ou um sal farmaceuticamente aceitável deste, e (ii) realização de 0, 1 ou 2 esquemas de tratamento subsequentes no indivíduo, em que cada esquema de tratamento subsequente compreende a administração de uma quantidade terapeuticamente eficaz de composto (1), ou um sal farmaceuticamente aceitável deste, em resposta a uma recorrência de sintomas de depressão. os (0, 1 ou 2) esquemas de tratamento subsequentes podem ser realizados ao longo de um período de 12 meses a partir do começo do esquema de tratamento inicial.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162501P | 2021-03-17 | 2021-03-17 | |
| US202163284592P | 2021-11-30 | 2021-11-30 | |
| PCT/US2022/020716 WO2022197901A1 (en) | 2021-03-17 | 2022-03-17 | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018607A2 true BR112023018607A2 (pt) | 2023-10-24 |
Family
ID=81327141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018607A BR112023018607A2 (pt) | 2021-03-17 | 2022-03-17 | Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4308162A1 (pt) |
| JP (1) | JP2024510436A (pt) |
| KR (1) | KR20230158033A (pt) |
| AU (1) | AU2022238365A1 (pt) |
| BR (1) | BR112023018607A2 (pt) |
| CA (1) | CA3213744A1 (pt) |
| IL (1) | IL305858A (pt) |
| TW (1) | TW202300156A (pt) |
| WO (1) | WO2022197901A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2986623T1 (sl) | 2013-04-17 | 2019-03-29 | Sage Therapeutics, Inc. | 19-NOR C3,3-disubstituirani C21-N-pirazolil steroidi in metode njhove uporabe |
| JP2019524853A (ja) | 2016-08-23 | 2019-09-05 | セージ セラピューティクス， インコーポレイテッド | 結晶性１９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイド |
| TW202005653A (zh) * | 2018-06-12 | 2020-02-01 | 美商賽吉醫療公司 | 19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
| KR20230041049A (ko) | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
-
2022
- 2022-03-17 AU AU2022238365A patent/AU2022238365A1/en active Pending
- 2022-03-17 KR KR1020237034937A patent/KR20230158033A/ko unknown
- 2022-03-17 WO PCT/US2022/020716 patent/WO2022197901A1/en active Application Filing
- 2022-03-17 CA CA3213744A patent/CA3213744A1/en active Pending
- 2022-03-17 JP JP2023554337A patent/JP2024510436A/ja active Pending
- 2022-03-17 BR BR112023018607A patent/BR112023018607A2/pt unknown
- 2022-03-17 EP EP22715444.0A patent/EP4308162A1/en active Pending
- 2022-03-17 TW TW111109951A patent/TW202300156A/zh unknown
- 2022-03-17 IL IL305858A patent/IL305858A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024510436A (ja) | 2024-03-07 |
| WO2022197901A1 (en) | 2022-09-22 |
| EP4308162A1 (en) | 2024-01-24 |
| KR20230158033A (ko) | 2023-11-17 |
| TW202300156A (zh) | 2023-01-01 |
| CA3213744A1 (en) | 2022-09-22 |
| AU2022238365A1 (en) | 2023-09-21 |
| IL305858A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023018607A2 (pt) | Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior | |
| Huang et al. | Roles of adenosine and its receptors in sleep–wake regulation | |
| Klawans et al. | Levodopa‐induced dopamine receptor hypersensitivity | |
| Burnstock | Purinergic signalling in endocrine organs | |
| Yamada et al. | Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents | |
| Bhat et al. | Histochemical localization of nitric oxide neurons in the hypothalamus: association with gonadotropin-releasing hormone neurons and co-localization with N-methyl-D-aspartate receptors | |
| BR112021018627A2 (pt) | Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia | |
| MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| BR112023022264A2 (pt) | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo | |
| MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
| Cardoso et al. | Physical exercise prevents memory impairment in an animal model of hypertension through modulation of CD39 and CD73 activities and A2A receptor expression | |
| Park et al. | Neuroprotective effect of citicoline against KA-induced neurotoxicity in the rat retina | |
| Li et al. | Effects of propofol on the activation of hippocampal CaMKIIα in depressed rats receiving electroconvulsive therapy | |
| JPWO2019241442A5 (pt) | ||
| Homayoun et al. | The effects of FK506 on the development and expression of morphine tolerance and dependence in mice | |
| MX2020003682A (es) | Metodos para tratar enfermedades asociadas con ciliopatias. | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| Park et al. | Electroacupuncture to ST36 ameliorates behavioral and biochemical responses to restraint stress in rats | |
| Kiviluoto et al. | Nitric oxide donors retard wound healing in cultured rabbit gastric epithelial cell monolayers | |
| Fujita | Report of the american heart association (AHA) scientific sessions 2012, Los Angeles | |
| MX2022006071A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa. | |
| Tominaga‐Yoshino et al. | Transient appearance of Ca2+‐permeable AMPA receptors is crucial for the production of repetitive LTP‐induced synaptic enhancement (RISE) in cultured hippocampal slices | |
| Higuchi et al. | Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report | |
| Li et al. | CGRP-mediated cardiovascular effect of nitroglycerin |